Covaxin 81% effective, works against UK variant, says Bharat Biotech
major Bharat Biotech on Wednesday said its Covid-19 vaccine, Covaxin, has demonstrated an interim vaccine efficacy of 81...
You are offline
Hyderabad based firm Bharat Biotech on Saturday informed that the company will pay compensation to the recipients in case of any ‘serious adverse’ effects experienced after receiving the antidote.Bharat Biotech has received a government purchase order for the supply of 55 lakh doses of Covaxin, an indigenous vaccine developed by Indian scientists.In the consent form to be signed by the vaccine recipients, Bharat Biotech said, “In case of any adverse events or serious adverse events, you will be provided medically recognised standard of care in the government designated and authorised centres and hospitals.â€The form also mentioned, “The compensation for serious adverse event will be paid by the sponsor (BBIL) in case if the SAE is proven to be causally related to the vaccine.â€Covaxin has demonstrated the ability to produce antidote against COVID-19 in phase 1 and 2 clinical trials.However, the clinical efficacy of the vaccine is yet to be established, and it is still being studied in phase 3 clinical trials.
View SourceRelated Notices
Covaxin works on coronavirus variant from UK
India’s homegrown Covid-19 vaccine, Covaxin, generates immune responses against the fast-spreading coronavirus variant...
91.6% Efficacy, Rare Adverse Effects: All You Need to Know About The Russian Sputnik V Vaccine
Russia’s COVID-19 vaccine Sputnik V on Monday received approval of Centre’s expert panel for emergency use in India ...
This notice has been removed
The content is no longer available
Bharat Biotech to pay compensation if Covaxin causes side effects
Hyderabad based firm Bharat Biotech on Saturday informed that the company will pay compensation to the recipients in case of any ‘serious adverse’ effects experienced after receiving the antidote.Bharat Biotech has received a government purchase order for the supply of 55 lakh doses of Covaxin, an indigenous vaccine developed by Indian scientists.In the consent form to be signed by the vaccine recipients, Bharat Biotech said, “In case of any adverse events or serious adverse events, you will be provided medically recognised standard of care in the government designated and authorised centres and hospitals.â€The form also mentioned, “The compensation for serious adverse event will be paid by the sponsor (BBIL) in case if the SAE is proven to be causally related to the vaccine.â€Covaxin has demonstrated the ability to produce antidote against COVID-19 in phase 1 and 2 clinical trials.However, the clinical efficacy of the vaccine is yet to be established, and it is still being studied in phase 3 clinical trials.
Recent Searches
Recent Noticeboards
Trending
No results found
Try a different search term
Something went wrong
No notices yet
No notices match these filters
Couldn't load notices
You're all caught up 🎉
Discussion (0)
No comments yet